Preeclampsia

Preeclampsia
Name	Preeclampsia
Field	Obstetrics
Symptoms	Hypertension, proteinuria, end-organ dysfunction
Complications	Eclampsia, HELLP syndrome, placental abruption
Onset	After 20 weeks' gestation
Risks	Nulliparity, prior history, chronic hypertension

Preeclampsia

Preeclampsia is a hypertensive disorder of pregnancy characterized by new-onset hypertension and multisystem involvement after 20 weeks of gestation, often accompanied by proteinuria or end-organ dysfunction. It can progress rapidly to life-threatening complications for the pregnant person and fetus, and its management typically involves surveillance, antihypertensive therapy, and timed delivery. Historical and contemporary figures in obstetrics, global health agencies, and landmark trials have shaped understanding and guidelines for this condition.

Signs and symptoms

Common presenting features include elevated blood pressure with readings often above 140/90 mmHg and proteinuria detected on urine testing, and may be associated with headache, visual disturbances, right upper quadrant pain, and edema. Prominent examples of symptoms—severe headache, cortical visual changes, and epigastric pain—carry risk for progression to seizures or liver dysfunction and are emphasized in clinical guidelines produced by organizations such as World Health Organization, American College of Obstetricians and Gynecologists, Royal College of Obstetricians and Gynaecologists, and National Institute for Health and Care Excellence. Fetal manifestations can include decreased fetal movements, oligohydramnios, and fetal growth restriction, monitored by fetal surveillance protocols influenced by studies from institutions like Mayo Clinic, Cleveland Clinic, and Johns Hopkins Hospital.

Pathophysiology

Pathophysiology involves abnormal placentation with impaired trophoblast invasion of spiral arteries, leading to uteroplacental ischemia, release of antiangiogenic factors, endothelial dysfunction, and systemic inflammation. Seminal laboratory and translational research from centers such as Harvard University, Stanford University, University of Oxford, and Karolinska Institutet has implicated altered levels of soluble fms-like tyrosine kinase-1, placental growth factor, and inflammatory cytokines in the cascade that produces hypertension and end-organ injury. Genetic and immunologic contributors have been explored in cohorts at institutions like Massachusetts General Hospital, University of California, San Francisco, and McGill University, while animal models used at research centers including Cold Spring Harbor Laboratory and Max Planck Society have helped delineate mechanisms linking placental ischemia to maternal vascular dysfunction.

Risk factors and prevention

Established risk factors include nulliparity, previous hypertensive pregnancy disorders, chronic hypertension, diabetes mellitus, renal disease, multifetal gestation, advanced maternal age, and certain autoimmune conditions; epidemiologic data from agencies like Centers for Disease Control and Prevention, World Bank, and United Nations reinforce socioeconomic and demographic contributions. Preventive approaches supported by randomized trials and guideline panels at Cochrane, National Institutes of Health, European Society of Cardiology, and professional societies include low-dose aspirin started in the first or early second trimester for high-risk individuals, calcium supplementation in populations with low dietary intake as investigated in trials sponsored by Bill & Melinda Gates Foundation and World Health Organization, and risk stratification algorithms developed with input from academic centers such as Imperial College London and University of Toronto.

Diagnosis

Diagnosis relies on documented hypertension after 20 weeks' gestation combined with proteinuria or signs of end-organ dysfunction including thrombocytopenia, impaired liver function, renal insufficiency, pulmonary edema, or cerebral/visual symptoms; diagnostic criteria are codified by bodies like American College of Obstetricians and Gynecologists, Royal College of Obstetricians and Gynaecologists, and International Society for the Study of Hypertension in Pregnancy. Laboratory testing often includes complete blood count, liver enzymes, serum creatinine, urinalysis with protein quantification, and biomarkers such as placental growth factor used in research settings at institutions like Karolinska Institutet and University of Cambridge. Imaging with fetal ultrasound and Doppler studies performed at centers like Mount Sinai Health System and Sheba Medical Center assesses fetal growth and placental perfusion.

Management and treatment

Management balances maternal stabilization and fetal maturity, typically including antihypertensive therapy (agents recommended by guidelines from American Heart Association, European Society of Cardiology, and World Health Organization), seizure prophylaxis with magnesium sulfate for severe disease as informed by landmark trials at Eunice Kennedy Shriver National Institute of Child Health and Human Development and World Health Organization, and timely delivery when maternal or fetal indications arise. Inpatient monitoring pathways and escalation protocols have been standardized in hospitals such as Brigham and Women's Hospital, UCSF Medical Center, and Toronto General Hospital, while corticosteroids to accelerate fetal lung maturity are used per obstetric consensus statements and trials conducted by groups like Vermont Oxford Network. Postpartum follow-up includes blood pressure monitoring, antihypertensive adjustment, and cardiovascular risk counseling drawing on research from Framingham Heart Study investigators and public health programs at Centers for Disease Control and Prevention.

Complications and prognosis

Complications include eclampsia (seizures), HELLP syndrome (hemolysis, elevated liver enzymes, low platelets), placental abruption, acute kidney injury, pulmonary edema, and long-term cardiovascular disease; these outcomes have been described in longitudinal cohorts from Johns Hopkins University, University of Pennsylvania, and University College London. Perinatal complications include preterm birth, fetal growth restriction, and stillbirth, reported in global surveillance by World Health Organization and United Nations Children's Fund. Prognosis varies with severity, gestational age at onset, and access to timely care; long-term monitoring for hypertension and ischemic heart disease is recommended based on evidence synthesized by American College of Cardiology and population studies from NHS and Australian Institute of Health and Welfare.

Epidemiology and public health

Incidence estimates range globally, influenced by geographic, socioeconomic, and healthcare access factors documented by World Health Organization, World Bank, Centers for Disease Control and Prevention, and national registries such as National Perinatal Epidemiology Unit and Perinatal Institute. Disparities in incidence and outcomes are noted across populations studied by researchers at University of California, Los Angeles, University of Chicago, and University of Cape Town, prompting public health initiatives and guideline development by entities including World Health Organization, Bill & Melinda Gates Foundation, UNICEF, and national ministries of health. Surveillance, education, and capacity-building programs implemented in collaboration with organizations like Doctors Without Borders, Red Cross, and PATH aim to reduce maternal and perinatal morbidity and mortality linked to hypertensive disorders of pregnancy.

Category:Obstetrics and gynecology